Figure S7 from Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors

Authors: Jun Sato, Yuki Katsuya, Takafumi Koyama et al.
Publication:
Published: Unknown date
Source: Crossref
Back to Search View Original Cite This Article

Abstract

<jats:p>&lt;p&gt;OS and PFS for patients evaluated at doses in dose expansion.&lt;/p&gt;</jats:p>

Keywords

patients evaluated doses dose expansionp

Related Articles

Supplementary Figure S3 from Pharmacologic Inhibition of PMS2 Induces MMR Deficiency and Response to Immune Checkpoint Blockade

Julian Blagg, Philippe Riou et al. - Unknown

Read More
Supplementary Table S2 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Marie-Anne Goyette, Christopher Graser et al. - Unknown

Read More
Supplementary Table S6 from &lt;i&gt;Helicobacter pylori&lt;/i&gt; Infection and Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis

Longgang Zhao, Yun Chen et al. - Unknown

Read More
Data from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Marie-Anne Goyette, Christopher Graser et al. - Unknown

Read More
Supplemental Table S4 from Performance of Statistical and Machine Learning Risk Prediction Models for Advanced Breast Cancer

Shuai Chen, Karla Kerlikowske et al. - Unknown

Read More
Journal Ideas PyMinds Charcha More
PORE

About

About Us

Resources

Help Centre Research Guides CiteScore

Legal

Terms of Service Privacy Policy Cookie Policy Accessibility

Connect

Contact Us
© 2026 PORE. Content available under CC BY-NC 4.0